Form 6-K GLAXOSMITHKLINE PLC For: Jul 19
FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For period ending 19 July 2016
GlaxoSmithKline plc
(Name of registrant)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)
Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F
Form 20-F x Form 40-F
--
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.
Yes No x
--
GlaxoSmithKline plc
(the 'Company')
Transaction notification
1. |
Details of PDMR/person closely associated with them ('PCA') | ||
a) |
Name |
Mr D R Troy | |
b) |
Position/status |
SVP & General Counsel | |
c) |
Initial notification/
amendment |
Initial notification | |
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
a) |
Name |
GlaxoSmithKline plc | |
b) |
LEI |
5493000HZTVUYLO1D793 | |
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||
a) |
Description of
The financial
instrument |
American Depositary Shares ('ADSs')
ISIN: US37733W1053
| |
b) |
Nature of
The transaction |
Acquisition of ADSs following the re-investment of dividends paid to shareholders on 14 July 2016 on ADSs held in the Company's US Deferred Performance Share Plan. | |
c) |
Price(s) and
volume(s) |
Price(s) |
Volume(s) |
$43.87 |
322.729 | ||
$43.87 |
5.128 | ||
d) |
Aggregated
information
Aggregated volume
Price |
337.852 ADSs
$43.87
| |
e) |
Date of the
transaction |
2016-07-14 | |
f) |
Place of
the transaction
|
New York Stock Exchange (XNYS) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
GlaxoSmithKline plc
(Registrant)
Date: July 19, 2016
By: VICTORIA WHYTE
----------------------
Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ROSEN, LEADING INVESTOR COUNSEL, Encourages Doximity, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – DOCS
- Omdia forecasts strong recovery in large-area display market for 2024, driven by sporting events and innovative production strategies
- Blackwell 3D Launches New Website, Eyes Project Development
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!